Clinical Trial Update: A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable [Phase 3]

View source ↗

Summary

Phase 3 trial assessing dupilumab for severe atopic dermatitis not controlled with cyclosporine A. Trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-20